• Publications
  • Influence
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.
HBY 097 [(S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3, 4-dihydroquinoxaline-2(1H)-thione] was selected from a series of quinoxalines as a nonnucleoside inhibitor of humanExpand
  • 75
  • 3
Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency
Human immunodeficiency virus type 2 (HIV-2)-related viruses were isolated from a Gambian dying of exclusively neurological disease (HIV-2D194) and from an asymptomatic Ghanian (HIV-2D205). BothExpand
  • 58
  • 1
  • PDF
Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.
S-2720 and other members of the quinoline/quinoxaline class of HIV-1-specific nonnucleoside reverse transcriptase inhibitors (NNRTIs) select for a glycine to glutamate substitution at residue 190Expand
  • 48
  • 1
Infection of monocytes/macrophages by HIV in vitro.
Because of the very important role of the mononuclear phagocyte system in the immunopathogenesis of HIV infection, a culture system for in vitro studies of infection of monocytes/macrophages with HIVExpand
  • 42
Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.
S-2720 [6-chloro-3,3-dimethyl-4-(isopropenyloxycarbonyl)-3,4- dihydroquinoxalin-2(1H)-thione], a quinoxaline derivative, was found to be a very potent inhibitor of both human immunodeficiency virusExpand
  • 113
Inhibition of HIV and virus replication by polysulphated polyxylan: HOE/BAY 946, a new antiviral compound.
Xylanpoly-(hydrogen sulphate) disodium salt with a molecular weight of about 6000 daltons (HOE/BAY 946) completely inhibited syncytium formation induced by the infection of T lymphocytes with HIV asExpand
  • 30
HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols.
A detailed structure-activity relationship of C2-symmetric diol inhibitors of HIV-1 protease leads to inhibitor 6 (HOE/BAY 793) which is outstanding in the inhibition of the enzyme and in theExpand
  • 17
Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
The human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase (RT) inhibitor quinoxaline S-2720 showed a more-potent inhibitory effect on HIV-1-induced cytopathicity in CEM cellsExpand
  • 39
Inhibition of HIV-1 protease by short peptides derived from the terminal segments of the protease.
The active HIV-1 protease is a homodimeric enzyme. A beta-sheet consisting of N- and C-terminal segments provides the main driving force for dimerization of the inactive protomers. Several shortExpand
  • 10
Inhibition of human immunodeficiency virus-1 protease by a C2-symmetrical phosphinic acid amide
Abstract The inhibition of HIV protease with C2-symmetric phosphinic acid based inhibitors is independent of the dissociation grade of the phosphinic acid. The corresponding amides are not only goodExpand
  • 4